Followers | 829 |
Posts | 119666 |
Boards Moderated | 16 |
Alias Born | 09/05/2002 |
Tuesday, January 30, 2024 10:41:45 AM
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-full-year-2023-results-and-reaffirms-full
4Q23 revenue was $14.2B, -42% YoY—but +8% YoY excluding COVID-related revenue. 4Q23 COVID-related revenue was $2.2B, down from $13.2B in 4Q22.
4Q23 GAAP and non-GAAP EPS were ($0.60) and $0.10, respectively. Both the GAAP and non-GAAP figures include a ($0.54) hit from the previously reported $3.5B reversal of Pavlovid sales to the US government; 4Q23 GAAP EPS (but not non-GAAP EPS) also includes a $1.4B non-cash writedown for Etrasimod (due to more conservative assumptions about new indications) and a $1B non-cash writedown for Prevnar-13 (which is now an obsolete product due to Prevar-20).
2024 guidance remains as per PFE’s press release of 12/13/23 (#msg-173417828). 2024 non-GAAP EPS guidance of $2.05-2.25 includes a negative $0.40 hit from SGEN, most of which stems from the net interest expense on the $43B of net debt PFE took on to fund the acquisition.
Note: The SGEN acquisition closed on 12/14/23, so SGEN’s sales and earnings were included in PFE’s 4Q23 results for only about 15% of the period, contributing ~$200M to sales.
4Q23 CC slides:
https://investors.pfizer.com/files/doc_financials/2023/q4/Q4-2023-Earnings-Charts-FINAL.pdf
CC prepared remarks (synched with slides):
https://s28.q4cdn.com/781576035/files/doc_financials/2023/q4/Q4-2023-Earnings-Conference-Call-Prepared-Remarks-FINAL.pdf
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Recent PFE News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 03:55:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 03:55:03 PM
- Chubb Stock Soars 9% with Berkshire Acquisition, AST SpaceMobile jumps 37% on AT&T deal, and More News • IH Market News • 05/16/2024 11:27:07 AM
- Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) • GlobeNewswire Inc. • 05/16/2024 10:00:45 AM
- Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting • PR Newswire (US) • 05/13/2024 12:00:00 PM
- Arm Sets 2025 Target for AI Chip Development, Amazon and Microsoft Commit Billions to French Investments, and More • IH Market News • 05/13/2024 11:16:03 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/09/2024 01:01:36 PM
- Bain Capital in Talks to Acquire PowerSchool; Blackstone Emerges Victorious in Hipgnosis Bidding War, and More News • IH Market News • 05/09/2024 11:53:19 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 07:56:17 PM
- Pfizer Announces New Chief Strategy and Innovation Officer • Business Wire • 05/06/2024 10:45:00 AM
- CVS Health, Starbucks, Shares Weaker; Pinterest Soars • IH Market News • 05/01/2024 01:12:05 PM
- Pfizer Reports First-Quarter 2024 Results • Business Wire • 05/01/2024 10:45:00 AM
- FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer • Business Wire • 04/29/2024 10:40:00 PM
- TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer • Business Wire • 04/29/2024 10:40:00 PM
- Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting • Business Wire • 04/29/2024 10:45:00 AM
- Anglo American Rejects BHP Group’s Offer, Toyota Invests $1.4 Billion in Indiana, and More News • IH Market News • 04/26/2024 11:48:07 AM
- U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B • Business Wire • 04/26/2024 10:45:00 AM
- Pfizer Declares Second-Quarter 2024 Dividend • Business Wire • 04/24/2024 08:37:00 PM
- Coca-Cola and Microsoft Sign Billion-Dollar Agreement, Apple Event Set for May 7, and More News • IH Market News • 04/24/2024 11:28:02 AM
- European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options • Business Wire • 04/22/2024 12:08:00 PM
- Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25 • Business Wire • 04/11/2024 02:00:00 PM
- Delta Generates US$37 Million Profit in Q1, Google and Intel Unveil Cutting-Edge AI Chips, and More News • IH Market News • 04/10/2024 11:13:48 AM
- Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease • Business Wire • 04/09/2024 10:45:00 AM
- ALTIVIA Appoints Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager • PR Newswire (US) • 04/08/2024 04:44:00 PM
- Super Micro Computer and Seagate Shares Surge on Analyst Optimism in Pre-Market Trading, and Latest News • IH Market News • 03/26/2024 11:20:49 AM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM